Abstract
Original language | English |
---|---|
Pages (from-to) | 199-207 |
Number of pages | 9 |
Journal | Pharmaceutical Development and Technology |
Volume | 14 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2009 |
Fingerprint
Dive into the research topics of 'Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: A preliminary study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Pharmaceutical Development and Technology, Vol. 14, No. 2, 2009, p. 199-207.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: A preliminary study
AU - Averineni, R.K.
AU - Sunderajan, S.G.
AU - Mutalik, S.
AU - Nayak, U.
AU - Shavi, G.
AU - Armugam, K.
AU - Meka, S.R.
AU - Pandey, S.
AU - Nayanabhirama, U.
N1 - Cited By :29 Export Date: 10 November 2017 CODEN: PDTEF Correspondence Address: Averineni, R. K.; Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, 576 104, Karnataka State, India; email: ranjith.kumar@manipal.edu Chemicals/CAS: chitosan, 9012-76-4; hydroxypropylmethylcellulose, 9004-65-3; taurocholic acid, 145-42-6, 59005-70-8, 81-24-3; valdecoxib, 181695-72-7; methylcellulose, 79484-92-7, 9004-67-5; Chitosan, 9012-76-4; Cyclooxygenase Inhibitors; Drug Carriers; Isoxazoles; Methylcellulose, 9004-67-5; Sulfonamides; Taurocholic Acid, 81-24-3; hypromellose, 8063-82-9; valdecoxib Tradenames: valus, Glenmark, India Manufacturers: Glenmark, India; Unichem, India References: Shojaei, A.H., Buccal mucosa as a route for systemic drug delivery: A review (1998) J. Pharm. Pharmaceut. Sci., 1, pp. 15-30; Joshi, M., Patravale, V., Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of valdecoxib (2006) Drug Dev. Ind. Pharmacy., 32, pp. 911-918; Sveinsson, S.J., Holbrook, P.W., Oral mucosa adhesive ointment containing liposomal corticosteroid (1993) Int. J. Pharm., 95, pp. 105-109; Schor, J.M., Davis, S.S., Nigalaye, A., Bolton, S., Sudarin transmucosal tablets (1983) Drug Dev. Ind. Pharm., 9, pp. 1359-1377; Ishida, M., Nambu, N., Nagai, T., Highly viscous gel ointment containing Carbopol for application to the oral mucosa (1983) Chem. Pharm. Bull., 31, pp. 4561-4564; Bremecker, K.D., Strempel, H., Klein, G., Novel concept for a mucosal adhesive ointment (1984) J. Pharm. Sci., 73, pp. 548-552; Sengodan, G., Vijayakumar, Mishra, D.N., Preparation, characterization and in vitro dissolution studies of solid systems of valdecoxib with chitosan (2006) Chem. Pharm. Bull., 54 (8), pp. 1102-1106; Blanco, M.D., Gomez, C., Olmo, R., Chitosan microspheres in PLG films as devices for cytarabine release (2000) Int. J. Pharm., 202, pp. 29-39; Anders, R., Merkle, H.P., Evaluation of laminated mucoadhesive films for buccal drug delivery (1989) Int. J. Pharm., 49, pp. 231-240; Guo, J.H., Bioadhesive polymer buccal films for buprenorphine controlled delivery: Formulation in vitro adhesion and release properties (1994) Drug Dev. Ind. Pharmacy., 20, pp. 2809-2821; Kohda, Y., Kobayashi, H., Baba, Y., Yuasa, H., Ozeki, T., Kanaya, Y., Sagara, E., Controlled release of lidocaine from buccal mucosa-adhesive films with solid dispersion (1997) Int. J. Pharm., 158, pp. 147-155; Wong, C.F., Yuen, K.H., Peh, K.K., Formulation and evaluation of controlled release Eudragit buccal films (1999) Int. J. Pharm., 178, pp. 11-22; Janes, K.A., Fresneau, M.P., Marazuela, A., Chitosan nanoparticles as delivery systems for doxorubicin (2001) J. Control Release., 73, pp. 255-267; Ruel, G.E., Chenite, A., Chaput, C., Characterization of thermosensitive chitosan gels for the sustained delivery of drugs (2000) Int. J. Pharm., 203, pp. 89-98; Muzarelli, R., Baldassarre, V., Conti, F., Biological activity of chitosan: Ultra structural study (1998) Biomaterials, 9, pp. 247-252; Senel, S., Ikinci, G., Kas, S., Chitosan films and hydrogels of cholhexidine gluconate for oral mucosal delivery (2000) Int. J. Pharm., 193, pp. 197-203; Ouchi, T., Banba, T., Fujimoto, M., Synthesis and antitumor activity of chitosan carrying 5-fluorouracil (1989) Makromol. Chem., 190, pp. 1817-1825; Jameela, S.R., Jayakrisnan, A., Glutaraldehyde cross-linked chitosan microspheres as a long acting biodegradable drug delivery vehicle: Studies on the in vitro release of mitoxantrone and in vivo degradation of microspheres in rat muscle (1995) Biomaterials, 16, pp. 769-775; Miwa, A., Ishibe, A., Nakano, M., Development of novel chitosan derivatives as micellar carriers of taxol (1998) Pharm. Res., 1, pp. 1844-1850; Micheal, T.J., Jame, H.S., Carlo, P., Nonsteroidal anti-inflammatory drugs as anticancer agent: Mechanistic, pharmacologic, and clinical issues (2002) J. Natl. Cancer. Inst., 94, pp. 252-266; Sawayangi, Y., Nambu, N., Nagai, T., Permeation of drugs through chitosan membranes (1982) Chem. Pharm. Bull., 30, pp. 3297-3301; Eouania, C., Piccerellea, P.H., Prinderrea, P., Bourretb, E., Joachima, J., In-vitro comparative study of buccal mucoadhesive performance of different polymeric films (2001) Euro. J. Pharm. Biopharm., 52, pp. 45-55; Peh, K.K., Wong, C.F., Polymeric films as vehicle for buccal delivery: Swelling, mechanical and bioadhesive properties (1999) J. Pharm. Pharm. Sci., 2, pp. 53-61; Parodi, B., Russo, E., Caviglioli, G., Cafaggi, S., Bignardi, G., Development and characterization of a buccoadhesive dosage form of oxycodone hydrochloride (1996) Drug Dev. Ind. Pharm., 22, pp. 445-450; Nakamura, F., Ohta, R., MacHida, Y., Nagai, T., In-vitro and in-vivo nasal mucoadhesion of some water-soluble polymers (1996) Int. J. Pharm., 134, pp. 173-181; Perioli, L., Ambrogi, P., Angelici, F., Ricci, M., Giovagnolia, S., Capuccellab, M., Rossia, C., Development of mucoadhesive patches for buccal administration of ibuprofen (2004) J. Control. Rel., 99, pp. 73-82; Lehr, C.M., Bouwstra, J.A., Schacht, E.H., Junginger, H.E., In-vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers (1992) Int. J. Pharm., 78, pp. 43-48; Panomsuk, S.P., Hatanaka, T., Aiba, T., Katayama, K., Koizumi, T., A study of the hydrophilic cellulose matrix: Effect of drugs on the swelling properties (1996) Chem. Pharm. Bull., 44, pp. 1039-1042; Bottenberg, P., Cleymaet, R., Muyncha, C.D., Remon, J.P., Coomans, D., Slop, D., Comparison of salivary fluoride concentration after administration of a bioadhesive slow-release tablet and a conventional fluoride tablet (1992) J. Pharm. Pharmacol., 44, pp. 684-686; Peppas, N.A., Mongia, N.K., Ultrapure poly (vinyl alcohol) with mucoadhesive drug delivery characteristics (1997) Eur. J. Pharm. Biopharm., 43, pp. 51-58; Zenriksen, I., Green, L., Smart, J.D., Smistad, G., Karlsen, J., Bioadhesion of hydrated chitosans: An in-vitro and in-vivo study (1996) Int. J. Pharm., 145, pp. 231-240; Peppas, N.A., Analysis of Fickian and non-Fickian drug release from polymers (1985) Pharmacut. Helv., 60, pp. 110-111; Rossi, S., Ferrari, F., Bonferoni, M.C., Caramella, C., Characterization of chitosan hydrochloride-mucin rheological interaction: Influence of polymer concentration and polymer:mucin weight ratio (2001) Eur. J. Pharm. Sci., 12 (479-485), pp. 208-215
PY - 2009
Y1 - 2009
N2 - The objective of the present study was to develop the mucoadhesive buccal film of valdecoxib for the treatment of oral sub mucous fibrosis, a localized buccal disease. Valdecoxib, a novel COX-2 inhibitor has been reported to be used in various osteopathic and rheumatoid conditions as oral therapy. The films were made out of chitosan and HPMC K4M as polymers. Sodium taurocholate was used as a permeation enhancer. All the formulations were examined for film thickness, swelling properties, drug content, weight variation, in vitro release studies, bioadhesive force, tensile strength, diffusion studies using pig mucosa and pharmacokinetic study in healthy male volunteers. Prepared films were thin, flexible, smooth and transparent. Bioadhesive force and tensile strength of the optimized formulation were found to be 75 ± 4 kg m-1 S-2 and more than 2.5 kg/3 cm2, respectively. The percent drug content was 98.5 ± 1.3%. The in vitro drug release from the selected formulation showed that about 69.34% of the drug payload was released up to 6 hours. The drug permeation through the dialysis sac and pig buccal mucosa was found to be 62.70% and 54.39%, respectively. Pharmacokinetic studies of the buccal mucoadhesive film showed that the drug was released locally at the target site of action, and a very small amount might have absorbed systemically. © 2009 Informa UK Ltd.
AB - The objective of the present study was to develop the mucoadhesive buccal film of valdecoxib for the treatment of oral sub mucous fibrosis, a localized buccal disease. Valdecoxib, a novel COX-2 inhibitor has been reported to be used in various osteopathic and rheumatoid conditions as oral therapy. The films were made out of chitosan and HPMC K4M as polymers. Sodium taurocholate was used as a permeation enhancer. All the formulations were examined for film thickness, swelling properties, drug content, weight variation, in vitro release studies, bioadhesive force, tensile strength, diffusion studies using pig mucosa and pharmacokinetic study in healthy male volunteers. Prepared films were thin, flexible, smooth and transparent. Bioadhesive force and tensile strength of the optimized formulation were found to be 75 ± 4 kg m-1 S-2 and more than 2.5 kg/3 cm2, respectively. The percent drug content was 98.5 ± 1.3%. The in vitro drug release from the selected formulation showed that about 69.34% of the drug payload was released up to 6 hours. The drug permeation through the dialysis sac and pig buccal mucosa was found to be 62.70% and 54.39%, respectively. Pharmacokinetic studies of the buccal mucoadhesive film showed that the drug was released locally at the target site of action, and a very small amount might have absorbed systemically. © 2009 Informa UK Ltd.
U2 - 10.1080/10837450802498928
DO - 10.1080/10837450802498928
M3 - Article
SN - 1083-7450
VL - 14
SP - 199
EP - 207
JO - Pharmaceutical Development and Technology
JF - Pharmaceutical Development and Technology
IS - 2
ER -